Published in Cancer Prev Res (Phila) on March 15, 2013
Vitamin D Effects on Prostate Pathology (DProstate) | NCT00741364
Vitamin D: Metabolism, Molecular Mechanism of Action, and Pleiotropic Effects. Physiol Rev (2016) 1.25
Nutrition, dietary interventions and prostate cancer: the latest evidence. BMC Med (2015) 0.98
Laser-capture Microdissection of Human Prostatic Epithelium for RNA Analysis. J Vis Exp (2015) 0.86
Differential expression and regulation of vitamin D hydroxylases and inflammatory genes in prostate stroma and epithelium by 1,25-dihydroxyvitamin D in men with prostate cancer and an in vitro model. J Steroid Biochem Mol Biol (2014) 0.86
Elevated serum microRNA levels associate with absence of high-grade prostate cancer in a retrospective cohort. PLoS One (2015) 0.85
Role of miR-100 in the radioresistance of colorectal cancer cells. Am J Cancer Res (2015) 0.84
The sum of many small changes: microRNAs are specifically and potentially globally altered by vitamin D3 metabolites. J Steroid Biochem Mol Biol (2013) 0.84
The histone demethylase PHF8 promotes prostate cancer cell growth by activating the oncomiR miR-125b. Onco Targets Ther (2015) 0.79
Vitamin D, intermediary metabolism and prostate cancer tumor progression. Front Physiol (2014) 0.79
Vitamin D and Immune Response: Implications for Prostate Cancer in African Americans. Front Immunol (2016) 0.78
Detection of 1α,25-dihydroxyvitamin D-regulated miRNAs in zebrafish by whole transcriptome sequencing. Zebrafish (2014) 0.78
In silico prediction and in vivo validation of Daphnia pulex microRNAs. PLoS One (2014) 0.77
Down-Regulation of Ca(2+)-Activated K⁺ Channel KCa1.1 in Human Breast Cancer MDA-MB-453 Cells Treated with Vitamin D Receptor Agonists. Int J Mol Sci (2016) 0.75
microRNAs and DICER1 are regulated by 1,25-dihydroxyvitamin D in prostate stroma. J Steroid Biochem Mol Biol (2017) 0.75
miR-486-3p, miR-139-5p, and miR-21 as Biomarkers for the Detection of Oral Tongue Squamous Cell Carcinoma. Biomark Cancer (2017) 0.75
Screening and Detection of Prostate Cancer-Review of Literature and Current Perspective. Indian J Surg Oncol (2017) 0.75
The miR-183 family cluster alters zinc homeostasis in benign prostate cells, organoids and prostate cancer xenografts. Sci Rep (2017) 0.75
New insights into vitamin D anticancer properties: focus on miRNA modulation. Mol Genet Genomics (2017) 0.75
MiRNAs and E2F3: a complex network of reciprocal regulations in human cancers. Oncotarget (2017) 0.75
MicroRNA expression profiles classify human cancers. Nature (2005) 69.12
The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell (1993) 64.62
A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A (2006) 40.09
EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J (2003) 9.55
MicroRNA expression profiling in prostate cancer. Cancer Res (2007) 8.04
Demographic differences and trends of vitamin D insufficiency in the US population, 1988-2004. Arch Intern Med (2009) 6.84
Cellular tumorigenicity in nude mice: correlation with cell growth in semi-solid medium. Cell (1974) 6.18
Widespread deregulation of microRNA expression in human prostate cancer. Oncogene (2007) 5.70
Do sunlight and vitamin D reduce the likelihood of colon cancer? Int J Epidemiol (2005) 5.52
Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int J Cancer (2010) 4.53
Androgen responsive adult human prostatic epithelial cell lines immortalized by human papillomavirus 18. Carcinogenesis (1997) 2.97
Vitamin D insufficiency. Mayo Clin Proc (2011) 2.89
Meta-analysis of observational studies of serum 25-hydroxyvitamin D levels and colorectal, breast and prostate cancer and colorectal adenoma. Int J Cancer (2011) 2.43
Ancient animal microRNAs and the evolution of tissue identity. Nature (2010) 2.35
Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland). Cancer Causes Control (2000) 2.24
miR-125b is methylated and functions as a tumor suppressor by regulating the ETS1 proto-oncogene in human invasive breast cancer. Cancer Res (2011) 2.22
A prospective study of plasma vitamin D metabolites, vitamin D receptor polymorphisms, and prostate cancer. PLoS Med (2007) 2.20
miR-99 family of MicroRNAs suppresses the expression of prostate-specific antigen and prostate cancer cell proliferation. Cancer Res (2011) 2.02
Decreased expression of miR-125b and miR-100 in oral cancer cells contributes to malignancy. Genes Chromosomes Cancer (2009) 1.98
MicroRNA let-7a inhibits proliferation of human prostate cancer cells in vitro and in vivo by targeting E2F2 and CCND2. PLoS One (2010) 1.94
Transcription factor E2F3 overexpressed in prostate cancer independently predicts clinical outcome. Oncogene (2004) 1.90
Cell-cell contact globally activates microRNA biogenesis. Proc Natl Acad Sci U S A (2009) 1.89
Clinical outcome prediction by microRNAs in human cancer: a systematic review. J Natl Cancer Inst (2012) 1.85
Randomized clinical trial of vitamin D3 doses on prostatic vitamin D metabolite levels and ki67 labeling in prostate cancer patients. J Clin Endocrinol Metab (2013) 1.81
Vitamin D-related genetic variation, plasma vitamin D, and risk of lethal prostate cancer: a prospective nested case-control study. J Natl Cancer Inst (2012) 1.79
MicroRNA-125b suppresses the development of bladder cancer by targeting E2F3. Int J Cancer (2011) 1.70
DNA binding alters coactivator interaction surfaces of the intact VDR-RXR complex. Nat Struct Mol Biol (2011) 1.59
miR-125b promotes growth of prostate cancer xenograft tumor through targeting pro-apoptotic genes. Prostate (2010) 1.55
Understanding the epidemiology, natural history, and key pathways involved in prostate cancer. Urology (2009) 1.47
MicroRNAs: key players in carcinogenesis and novel therapeutic targets. Eur J Surg Oncol (2008) 1.42
Vitamin D and the epidemiology of prostate cancer. Semin Dial (2005) 1.41
Polo-like kinase 1 is overexpressed in prostate cancer and linked to higher tumor grades. Prostate (2004) 1.40
Vitamin D receptor protein expression in tumor tissue and prostate cancer progression. J Clin Oncol (2011) 1.39
MiR-100 regulates cell differentiation and survival by targeting RBSP3, a phosphatase-like tumor suppressor in acute myeloid leukemia. Oncogene (2011) 1.35
Change in expression of miR-let7c, miR-100, and miR-218 from high grade localized prostate cancer to metastasis. Urol Oncol (2009) 1.33
MicroRNAs181 regulate the expression of p27Kip1 in human myeloid leukemia cells induced to differentiate by 1,25-dihydroxyvitamin D3. Cell Cycle (2009) 1.33
Inhibition of p38 by vitamin D reduces interleukin-6 production in normal prostate cells via mitogen-activated protein kinase phosphatase 5: implications for prostate cancer prevention by vitamin D. Cancer Res (2006) 1.28
MicroRNA-32 upregulation by 1,25-dihydroxyvitamin D3 in human myeloid leukemia cells leads to Bim targeting and inhibition of AraC-induced apoptosis. Cancer Res (2011) 1.26
MicroRNA-22 is induced by vitamin D and contributes to its antiproliferative, antimigratory and gene regulatory effects in colon cancer cells. Hum Mol Genet (2012) 1.26
Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system. Urology (1997) 1.24
Regulation of placenta growth factor by microRNA-125b in hepatocellular cancer. J Hepatol (2011) 1.20
Effects of 1α,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer (2011) 1.20
25-Hydroxyvitamin D3, the prohormone of 1,25-dihydroxyvitamin D3, inhibits the proliferation of primary prostatic epithelial cells. Cancer Epidemiol Biomarkers Prev (2000) 1.18
mRNA and micro-RNA expression analysis in laser-capture microdissected prostate biopsies: valuable tool for risk assessment and prevention trials. Exp Mol Pathol (2009) 1.17
Vitamin D and vitamin D analogs as cancer chemopreventive agents. Nutr Rev (2003) 1.16
Molecular mechanisms mediating the anti-proliferative effects of Vitamin D in prostate cancer. J Steroid Biochem Mol Biol (2005) 1.14
1,25-Dihydroxyvitamin D3 induces morphological and biochemical markers of apoptosis in MCF-7 breast cancer cells. J Steroid Biochem Mol Biol (1996) 1.12
Sequential analysis of multistage hepatocarcinogenesis reveals that miR-100 and PLK1 dysregulation is an early event maintained along tumor progression. Oncogene (2012) 1.11
Vitamin D3 supplementation at 4000 international units per day for one year results in a decrease of positive cores at repeat biopsy in subjects with low-risk prostate cancer under active surveillance. J Clin Endocrinol Metab (2012) 1.08
MiR-100 resensitizes docetaxel-resistant human lung adenocarcinoma cells (SPC-A1) to docetaxel by targeting Plk1. Cancer Lett (2011) 1.01
Protection against cellular stress by 25-hydroxyvitamin D3 in breast epithelial cells. J Cell Biochem (2010) 0.97
Phase I study of weekly DN-101, a new formulation of calcitriol, in patients with cancer. Cancer Chemother Pharmacol (2006) 0.95
Nongenomic and genomic effects of 1α,25(OH)2 vitamin D3 in rat testis. Life Sci (2011) 0.81
Expression patterns of vitamin D receptor in human prostate. J Cell Biochem (2001) 0.80
Determination of 1,25-dihydroxyvitamin D concentrations in human colon tissues and matched serum samples. Anticancer Res (2012) 0.79
Estimates of optimal vitamin D status. Osteoporos Int (2005) 7.13
Metformin use and all-cause and prostate cancer-specific mortality among men with diabetes. J Clin Oncol (2013) 4.75
The urgent need to recommend an intake of vitamin D that is effective. Am J Clin Nutr (2007) 4.36
Risk assessment for vitamin D. Am J Clin Nutr (2007) 4.34
Active surveillance of small renal masses: progression patterns of early stage kidney cancer. Eur Urol (2011) 3.75
Outcomes of small renal mass needle core biopsy, nondiagnostic percutaneous biopsy, and the role of repeat biopsy. Eur Urol (2011) 3.51
30-day mortality and major complications after radical prostatectomy: influence of age and comorbidity. J Natl Cancer Inst (2005) 3.26
A framework for the identification of men at increased risk for prostate cancer. J Urol (2009) 3.07
Predictors of pathological progression among men with localized prostate cancer undergoing active surveillance: a sub-analysis of the REDEEM study. J Urol (2013) 2.65
Association of vitamin D with insulin resistance and beta-cell dysfunction in subjects at risk for type 2 diabetes. Diabetes Care (2010) 2.61
Comparison of vitamin D2 and vitamin D3 supplementation in raising serum 25-hydroxyvitamin D status: a systematic review and meta-analysis. Am J Clin Nutr (2012) 2.56
A prospective nested case-control study of vitamin D status and pancreatic cancer risk in male smokers. Cancer Res (2006) 2.53
Impact of a multi-disciplinary patient education session on accrual to a difficult clinical trial: the Toronto experience with the surgical prostatectomy versus interstitial radiation intervention trial. J Clin Oncol (2006) 2.50
An evaluation of automated methods for measurement of serum 25-hydroxyvitamin D. Clin Biochem (2009) 2.41
Evidence for a biopsy derived grade artifact among larger prostate glands. J Urol (2006) 2.23
The case against ergocalciferol (vitamin D2) as a vitamin supplement. Am J Clin Nutr (2006) 2.19
Variability in diagnostic opinion among pathologists for single small atypical foci in prostate biopsies. Am J Surg Pathol (2010) 2.16
Long-term follow-up of T1 high-grade bladder cancer after intravesical bacille Calmette-Guérin treatment. BJU Int (2010) 2.14
Diminished efficacy of Bacille Calmette-Guérin among elderly patients with nonmuscle invasive bladder cancer. Urology (2011) 2.07
Information needs of men on androgen deprivation therapy. BJU Int (2011) 2.02
Rationale for percutaneous biopsy and histologic characterisation of renal tumours. Eur Urol (2012) 1.95
Clinical, environmental, and genetic determinants of multiple sclerosis in children with acute demyelination: a prospective national cohort study. Lancet Neurol (2011) 1.92
13th Workshop consensus for vitamin D nutritional guidelines. J Steroid Biochem Mol Biol (2007) 1.83
Randomized clinical trial of vitamin D3 doses on prostatic vitamin D metabolite levels and ki67 labeling in prostate cancer patients. J Clin Endocrinol Metab (2013) 1.81
Common genetic variants of the vitamin D binding protein (DBP) predict differences in response of serum 25-hydroxyvitamin D [25(OH)D] to vitamin D supplementation. Clin Biochem (2009) 1.80
The role of magnetic resonance imaging in targeting prostate cancer in patients with previous negative biopsies and elevated prostate-specific antigen levels. BJU Int (2009) 1.75
Unintended consequences of laparoscopic surgery on partial nephrectomy for kidney cancer. J Urol (2009) 1.71
Evidence-based criteria in the nutritional context. Nutr Rev (2010) 1.68
Development of prostate cancer quality indicators: a modified Delphi approach. Can J Urol (2005) 1.59
Effect of vitamin D replacement on musculoskeletal parameters in school children: a randomized controlled trial. J Clin Endocrinol Metab (2005) 1.59
Results of a national population-based study of outcomes of surgery for renal tumors associated with inferior vena cava thrombus. Urology (2013) 1.58
Prostate volume is strongest predictor of cancer diagnosis at transrectal ultrasound-guided prostate biopsy with prostate-specific antigen values between 2.0 and 9.0 ng/mL. Urology (2007) 1.58
Laparoscopic partial nephrectomy: 3-year followup. J Urol (2006) 1.57
miR-183-96-182 cluster is overexpressed in prostate tissue and regulates zinc homeostasis in prostate cells. J Biol Chem (2011) 1.55
Vitamin D and reduced risk of breast cancer: a population-based case-control study. Cancer Epidemiol Biomarkers Prev (2007) 1.55
Guideline for optimization of surgical and pathological quality performance for radical prostatectomy in prostate cancer management: evidentiary base. Can Urol Assoc J (2010) 1.55
Pathological, oncologic and functional outcomes of radical prostatectomy following active surveillance. J Urol (2013) 1.54
Efficacy of a second line luteinizing hormone-releasing hormone agonist after advanced prostate cancer biochemical recurrence. J Urol (2011) 1.54
Contemporary results of percutaneous biopsy of 100 small renal masses: a single center experience. J Urol (2008) 1.53
Optimal management of high-risk T1G3 bladder cancer: a decision analysis. PLoS Med (2007) 1.53
Effects of lycopene on protein expression in human primary prostatic epithelial cells. Cancer Prev Res (Phila) (2013) 1.53
Cod liver oil, vitamin A toxicity, frequent respiratory infections, and the vitamin D deficiency epidemic. Ann Otol Rhinol Laryngol (2008) 1.53
Ipsilateral adrenalectomy at the time of radical nephrectomy impacts overall survival. BJU Int (2012) 1.50
Cost-effectiveness analysis of immediate radical cystectomy versus intravesical Bacillus Calmette-Guerin therapy for high-risk, high-grade (T1G3) bladder cancer. Cancer (2009) 1.50
Complications of laparoscopic partial nephrectomy in 200 cases. J Urol (2005) 1.50
The role of bisphosphonates in the management of bone metastases in prostate cancer. Can J Urol (2004) 1.49
Evidence for genetic regulation of vitamin D status in twins with multiple sclerosis. Am J Clin Nutr (2008) 1.49
'Prostatic evasive anterior tumours': the role of magnetic resonance imaging. BJU Int (2009) 1.48
Safety of vitamin D3 in adults with multiple sclerosis. Am J Clin Nutr (2007) 1.48
Impact of multiparametric endorectal coil prostate magnetic resonance imaging on disease reclassification among active surveillance candidates: a prospective cohort study. J Urol (2012) 1.47
Measurement of peri-prostatic fat thickness using transrectal ultrasonography (TRUS): a new risk factor for prostate cancer. BJU Int (2012) 1.46
Median 5 year follow-up of 125iodine brachytherapy as monotherapy in men aged<or=55 years with favorable prostate cancer. Urology (2009) 1.45
Laparoscopic repair of vesicovaginal fistula. J Urol (2005) 1.42
Longitudinal study of vitamin D metabolites after long bone fracture. J Bone Miner Res (2013) 1.42
Active surveillance failure for prostate cancer: does the delay in treatment increase the risk of urinary incontinence? Can J Urol (2012) 1.42
Laparoscopic radical nephrectomy for large (greater than 7 cm, T2) renal tumors. J Urol (2004) 1.41
Current textbooks and anatomy of the prostate--a case for an update. BJU Int (2009) 1.41
Short- and long-term safety of weekly high-dose vitamin D3 supplementation in school children. J Clin Endocrinol Metab (2008) 1.41
Impact of 5-alpha reductase inhibitors on men followed by active surveillance for prostate cancer: a time-dependent covariate reanalysis. Eur Urol (2013) 1.39
Comparison of health-related quality of life 5 years after SPIRIT: Surgical Prostatectomy Versus Interstitial Radiation Intervention Trial. J Clin Oncol (2010) 1.37
Prospective, randomized comparison of transperitoneal versus retroperitoneal laparoscopic adrenalectomy. J Urol (2005) 1.36
Comparison of daily, weekly, and monthly vitamin D3 in ethanol dosing protocols for two months in elderly hip fracture patients. J Clin Endocrinol Metab (2008) 1.35
Clinical predictors of Gleason score upgrading: implications for patients considering watchful waiting, active surveillance, or brachytherapy. Cancer (2007) 1.35
Impact of androgen-deprivation therapy on cognitive function in men with nonmetastatic prostate cancer. J Clin Oncol (2010) 1.34
Impact of positive surgical margins after radical prostatectomy differs by disease risk group. J Urol (2010) 1.33
Prevalence of prostate cancer on autopsy: cross-sectional study on unscreened Caucasian and Asian men. J Natl Cancer Inst (2013) 1.32
Gene expression patterns in the human breast after pregnancy. Cancer Prev Res (Phila) (2010) 1.31
No association between 25-hydroxyvitamin D and mammographic density. Cancer Epidemiol Biomarkers Prev (2006) 1.31
Organ donation breakthrough collaborative: increasing organ donation through system redesign. Crit Care Nurse (2006) 1.31
US organ donation breakthrough collaborative increases organ donation. Crit Care Nurs Q (2008) 1.30
Differences between urologists in United States and Canada in approach to bladder cancer. Urology (2005) 1.28
Association of 25(OH)D and PTH with metabolic syndrome and its traditional and nontraditional components. J Clin Endocrinol Metab (2010) 1.28
Discovery of novel hypermethylated genes in prostate cancer using genomic CpG island microarrays. PLoS One (2009) 1.28
Regulation of prostaglandin metabolism by calcitriol attenuates growth stimulation in prostate cancer cells. Cancer Res (2005) 1.27
Management of skeletal-related events in patients with advanced prostate cancer and bone metastases: Incorporating new agents into clinical practice. Can Urol Assoc J (2012) 1.27
Use of complementary/alternative medicine by men diagnosed with prostate cancer: prevalence and characteristics. Urology (2003) 1.26
Focal laser ablation for prostate cancer followed by radical prostatectomy: validation of focal therapy and imaging accuracy. Eur Urol (2010) 1.25
Troubling outcomes from population-level analysis of surgery for upper tract urothelial carcinoma. Urology (2010) 1.25
Publication rate of abstracts presented at the annual meeting of the American Urological Association. BJU Int (2004) 1.23
Surgical wait times for patients with urological cancers: a survey of Canadian surgeons. Can J Urol (2006) 1.21
Using the Delphi technique to improve clinical outcomes through the development of quality indicators in renal cell carcinoma. J Oncol Pract (2013) 1.21